Spectrum Pharmaceuticals, Inc.

SPPI

On August 6, 2021, Spectrum announced that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding the Company’s Biologics License Application for ROLONTIS® (eflapegrastim). The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company’s manufacturing facility will be necessary. On this news shares of Spectrum stock traded down over 25%.

Lead Plaintiff deadline
November 1, 2021
class period
December 27, 2018
to
August 5, 2021
Case Documents
No documents available. Contact us if you need a case document.